View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 17, 2021updated 11 Jul 2022 2:19pm

Molecular Partners to suspend subject enrolment in Phase III Covid-19 trial

In the trial, ensovibep did not meet the thresholds needed to progress subject enrolment. 

Molecular Partners has announced plans to stop the recruitment of hospitalised adult Covid-19 patients in the Phase III ACTIV-3 clinical trial of its DARPin therapeutic candidate, ensovibep.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

After a futility analysis, it was found that ensovibep did not meet the thresholds needed to progress subject enrolment.

The candidate is designed to act on the spike protein of the SARS-CoV-2 virus at three sites to hinder viral escape through mutation.

According to in vitro data, ensovibep possesses the ability to impede all known variants of concern, including Delta.

Carried out by the US National Institutes of Health (NIH), the international Phase III ACTIV-3 platform trial is part of the ACTIV programme.

ACTIV assesses various drugs to treat Covid-19 to find their benefits compared with the current standard of care.

Nealy 470 subjects were enrolled in the ensovibep arm of the trial at the time of futility analysis.

The independent Data and Safety Monitoring Board (DSMB) advised halting the enrolment of hospitalised subjects in the ensovibep group of the trial following the futility analysis.

Molecular Partners CEO Patrick Amstutz said: “Demonstrating efficacy in hospitalised patients with Covid-19 has proven particularly challenging for antiviral therapies, with most investigational agents tested so far in the ACTIV-3 study not passing futility criteria – potentially due to the multi-systemic inflammatory component of late-stage Covid-19 disease.”

Molecular Partners and Novartis partnered to develop ensovibep and are now assessing the drug in another international Phase II/III trial named EMPATHY.

This trial is analysing the ability of ensovibep to quickly reduce viral load, as well as avert worsening symptoms and hospital admission in individuals in the early stages of Covid-19.

Topline interim results from 400 subjects in the EMPATHY trial is anticipated early next year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena